CGTX (Cognition Therapeutics, Inc.) רווח נקי למניה (EPS TTM)

Cognition Therapeutics (CGTX) is developing methods to restore neural connections in Alzheimer's disease, relying on strict FDA oversight in its research. Precision logistics for biomaterials through a network of laboratories ensure supply chain stability. The 12-month rolling EPS value on GURU.Markets confirms these data, where the current figure stands at -0.18, helping to distinguish actual yield from market noise.
פילוחים אנליטיים ודוחות נתונים של חברת Cognition Therapeutics Inc. (CGTX)

For Cognition Therapeutics (CGTX), the trailing 12-month EPS reflects the biotech's financial resilience against reagent supply disruptions and international licensing complexities. This metric is calculated as the ratio of total annual net income to the weighted average number of shares, allowing investors to assess the actual efficiency of value generation per share of capital regardless of quarterly fluctuations.